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ABSTRACT:  
Objectives- To utilize a non-biased assay of circulating tumour cells (CTCs) in prostate cancer (PCa) patients in 
order to identify non-traditional CTC phenotypes potentially excluded by conventional detection methods reliant 
upon antigen and/or sized based enrichment.  
Patients and Methods- 41 metastatic castration resistant prostate cancer (mCRPC) patients and 20 healthy 
volunteers were analysed on the Epic CTC Platform, via high throughput imaging of DAPI expression and 
CD45/cytokeratin (CK) immunofluorescence (IF) in all circulating nucleated cells plated on glass slides. IF for 
androgen receptor [AR] expression, and FISH for PTEN and ERG confirmed PCa origin of CTCs.  
Results-Traditional (t) CTCs (CD45-/CK+/morphologically distinct) were identified in 100% mCRPC patients. 
Using the above markers, we identified non-traditional CTCs in mCRPC patients, including CK- and apoptotic 
CTCs. Small CTCs (≤WBC size) were identified in 98% of mCRPC patients. Total, traditional and non-traditional 
CTCs were significantly increased in deceased vs. living patients at 18 months; however only non-traditional CTCs 
associated with overall survival. Traditional and total CTC counts by the Epic platform in the mCRPC cohort were 
also significantly correlated with CTC counts by the CellSearch system.  
Conclusions- Heterogeneous non-traditional CTC populations that may be missed by other approaches are frequent 
in mCRPC; characterization of non-traditional CTCs  may provide additional prognostic or predictive information.  
Key words: Circulating tumour cells, liquid biopsy, metastatic castration resistant prostate cancer, ERG, PTEN 
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INTRODUCTION: 
 Dissemination of cancer cells from primary sites into circulation and seeding of metastases is the 
underlying cause of mortality for most non-hematopoietic malignancies. Detection and enumeration of circulating 
tumour cells (CTCs) is associated with decreased progression-free survival and overall survival for a variety of 
tumours, including prostate cancer (PCa) [1-3]. Based on these findings, CTC enumeration could be a valuable tool 
for disease response and progression monitoring. Additionally, CTCs can also be characterized for predictive 
biomarkers. Given that CTCs circulate at very low concentrations (10-6-10-7) [4], detection in millilitres of blood 
requires extremely sensitive and specific methods. Numerous technologies have been developed to this end [5, 6], 
with the majority requiring an enrichment step based on differences in various physical (size and/or density) or 
biological parameters (surface marker expression) to distinguish CTCs from surrounding hematopoietic cells. For 
example, the CellSearch® Circulating Tumor Cell System, the only FDA cleared method for CTC detection [7], 
requires cells to contain a DAPI-intact nucleus, lack expression of the hematopoietic marker CD45, express 
epithelial cell adhesion molecule (EpCAM) and cytokeratin (CK), and have a diameter larger than 4 µm [7]. 
Enrichment technologies however will potentially fail to capture non-traditional tumour cells lacking the selected 
characteristic.   
 Indeed, recent reports utilizing non-EpCAM or size based selection techniques have underscored this point, 
revealing PCa CTCs with non-traditional phenotypes, describing heterogeneity in size [8], epithelial marker 
expression [9], cell integrity [10], and proliferation rate [11]; both between and within individual patients. CTCs 
isolated from men with metastatic PCa have also shown evidence of epithelial-mesenchymal transition (EMT), via 
detection of EMT related transcription factors, expression of N-cadherin and vimentin, and loss of CK and E-
cadherin expression [9].   However, the degree and scope of this heterogeneity within PCa CTC populations is 
incompletely described, as most approaches are only able to assess heterogeneity in a single parameter.   
   Numerous studies have identified a relationship between CTC counts and disease progression or overall 
survival in metastatic castrate-resistant prostate cancer (mCRPC) [2, 3]. These studies have been based on single-
parametric enrichment technologies which likely miss non-traditional CTC phenotypes that may have prognostic or 
therapeutic significance. Here, we utilize a non-biased assay technique (the Epic CTC platform) that retains all 
nucleated cells and interrogates them in a multi-parametric fashion, analysing size, shape, DAPI staining and 
immunofluorescence (IF) antigen characterization (typically CD45 and CK expression). Concurrently, we evaluated 
both traditional (CD45-, CK+, morphologically distinct) and candidate non-traditional CTCs for PCa-specific 
molecular aberrations, including androgen receptor (AR) expression by IF, and PTEN deletion and ERG 
rearrangement by fluorescence in situ hybridization (FISH) [12-15]. Through this approach, we demonstrate that 
patients with mCRPC harbour a variety of non-traditional CTC phenotypes. 
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PATIENTS AND METHODS 
Sample Collection and Handling: 
 Whole blood samples were obtained from 41 unique patients, required to have histologically or 
biochemically confirmed prostate adenocarcinoma and planned for initiation of a new treatment for progressive 
mCRPC in the presence of castrate levels of serum testosterone (<50 ng per decilitre [1.73 nmol per litre]), 
consistent with Prostate Cancer Clinical Trials Working Group 2 (PCWG2) guidelines. After collection at the 
Royal Marsden, Sutton, UK, samples were shipped to Epic Sciences (San Diego, CA, USA) at ambient 
temperature. Sample collection for this study was approved by The Royal Marsden (London, UK) Research Ethics 
Committee (REC 04/Q0801/6) and by The Royal Marsden Committee for Clinical Research. Additionally, 21 
samples were obtained from 20 consenting healthy adults by The Institute of Cancer Research (London, U.K.) or 
Epic Sciences (San Diego, CA, USA) and processed in the same manner as patient samples. All samples were 
collected with informed consent. Patient and healthy volunteer demographics are summarized in Table 1. The 
median blood sample transit time for patient samples was 32 hours with a range of 28-78 hours. Additional draws 
from select patients were evaluated as needed for FISH.  
 
Blood sample preparation and storage: 
Upon sample receipt, red blood cells were lysed and nucleated cells dispensed onto glass microscope slides 
according to methods previously described [16-18]. Up to 12 slides were prepared from each blood sample at 3x106 
cells/slide. Slides were then stored at -80°C (stable for longer than one year, unpublished data). The number of 
slides created from each individual sample was determined by the volume of blood received and the white blood 
cell (WBC) count.  
 
CTC identification and protein characterization on the Epic platform: 
For CTC analysis, two slides from each patient sample were thawed, then stained by IF to distinguish CTCs 
from WBCs as described previously [16-18]. In addition to DAPI, CD45, and CK, an additional antibody targeting 
the N-terminal region of AR (clone D6F11, Cell Signalling Technology, Danvers, MA, USA) was utilized, capable 
of detecting full length and LBD-truncated variants of the protein. Stained slides were imaged on a high-speed 
fluorescent imaging system. Captured images were analysed by an automated algorithm that characterizes each cell 
by more than 90 parameters, including protein expression and morphology to distinguish CTCs from normal 
nucleated cells. All CTC candidates were then reviewed by trained technicians, and CK+/CD45- cells with intact, 
DAPI+ nuclei exhibiting tumour-associated morphologies were classified as traditional CTCs. The trained 
technicians were blinded as to whether the sample was from a cancer patient or healthy donor.  Candidate CTCs 
that did not meet the criteria for traditional CTC, as described in the Results, were identified as CD45-/CK- cells 
with abnormal morphology or apoptotic CTCs (CD45- with characteristic nuclear fragmentation or condensation). 
In a separate subsequent analysis, cell morphological characteristics, including cell area, were determined for each 
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CTC by Epic proprietary software. Analysis was reviewed by a Board certified Anatomic Pathologist with 
experience in genitourinary pathology and molecular characterization of mCRPC (S.A.T.) to confirm cancer origin.   
 
CTC analysis via CellSearch Assay: 
 CTC isolation and enumeration were carried out using the CellSearch™ system (Janssen Diagnostics, 
Raritan, NJ, USA) according to the manufacturer’s instructions. Blood samples were drawn into CellSave™ tubes 
(Janssen Diagnostics) and samples were kept at room temperature and processed within 72 h of collection. To 
calculate the CTC count, 7.5 ml of blood was enriched immunomagnetically using anti-EpCAM antibodies, 
followed by fluorescent labelling and individual capture using a four-colour semiautomated fluorescent microscope. 
The images were then presented to trained operators, who selected cells that met the definition of CTC.  Criteria 
used to define a CTC include round to oval morphology, size >5 μm, a visible nucleus (4′,6-diamidino-2-
phenylindole positive), positive staining for cytokeratins 8,18 and/or 19 (phycoerythrin) and negative staining for 
CD45 (allophycocyanin). Results were expressed as the number of cells per 7.5 ml of blood. 
 
CTC FISH analysis:   
Following CTC IF analysis, a subset of slides with a sufficient number of CTCs was tested for PTEN loss 
or ERG rearrangements by fluorescence in situ hybridization (FISH). Coverslips were removed and slides were 
hybridized using a two-color probe solution targeting either PTEN and chromosome 10 centromere (CC10) DNA 
sequences or regions flanking 5’ and 3’ ERG (Cymogen Dx, New Windsor, NY, USA). After processing, slides 
were counterstained with DAPI and mounted with an anti-fade mounting medium. Epic software was used to 
relocate CTCs for scoring. A minimum of 20 WBCs on each slide were also scored as internal controls.  
PTEN loss was defined by a cell containing fewer PTEN signals than CC10 signals or only one of each 
signal (loss of chromosome 10). Cells with no PTEN signals and at least one CC10 signal were classified as 
homozygous PTEN loss (HO). Heterozygous PTEN loss (HE) cells contained at least one PTEN signal and either 
more CC10 signals than PTEN or one PTEN signal and one CC10 signal. Cells with a 1:1 ratio of PTEN:CC10 and 
at least two of each signal were considered PTEN non-deleted. ERG rearrangements can present as a split of the 5’ 
and 3’ FISH signals (representing ERG fusions though insertion, inversion or translocation) or as a deletion of the 
5’ FISH signal (representing TMPRSS2:ERG fusions through deletion of the intervening region on chromosome 
21). Hence, cells were considered ERG-rearranged if a separation of at least one pair of 5’ and 3’ ERG signals (by a 
distance of at least 2 signal diameters) or a deletion of at least one 5’ ERG signal was observed. Cells in which all 
3’ ERG signals had a corresponding 5’ ERG signal within two signal diameters were considered ERG non-
rearranged. 
  
 
Statistical Analysis: 
Correlations/associations of traditional and non-traditional CTC counts and clinicopathological parameters 
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were assessed by Spearman rank correlation, two-sided Mann-Whitney tests, Kruskal-Wallis tests or Kaplan-Meier 
analysis using MedCalc v 15.6 (MedCalc Software bvba, Belgium). Area under the curve (AUC) from receiver 
operator characteristic (ROC) curves was determined using MedCalc v 15.6 for traditional and non-traditional CTC 
counts for predicting mCRPC vs. healthy volunteer status. Youden index CTC/mL cutoff, value, and CTC cutoffs 
with sensitivity and specificity at 100% specificity and sensitivity, respectively, were determined as part of the 
ROC analysis. Kaplan-Meier analysis was performed by stratifying patients per CTC type into those with ≤ vs. > 
median CTC count. For all tests, p values < 0.05 were considered significant. 
   
RESULTS 
Detection of Traditional CTCs in mCRPC patients 
 A total of 41 blood samples from 41 mCRPC patients and 21 blood samples from 20 healthy volunteers 
were analysed. Patient and healthy volunteer demographics are shown in Table 1. An average of 11 slides per 
patient was plated (range 4 to 16) from an average blood volume of 7.0 mL per patient (range 3.68-7.83 mL). 
Traditional CTCs were defined (described previously [16-18]) as cells with an intact, DAPI-positive nucleus 
lacking features of apoptosis, absence of CD45 staining (CD45-) and positive CK staining (CK+) (Figure 1). 
Additionally, traditional CTCs were required to have characteristic cytomorphologic features consistent with 
malignancy (including nucleomegaly, nuclear membrane irregularity, eccentric cytoplasmic distribution, and 
polygonal/elongated cell shapes) [16-19]. Using this traditional CTC definition, 41/41 (100%) mCRPC patients had 
detectable traditional CTCs (median 5/mL, range 1-121) and 22/41 (54%) had >4/mL.  
 When two or more adjacent traditional CTCs were identified, they were classified as CTC clusters. CTC 
clusters were detected in 7/41 (17%) patients (median 0/mL, range 0-6) (Figure 1). Of 20 healthy volunteers tested, 
none had >4 events in 1mL meeting the definition for a traditional CTC and five (25%) had 1-4/mL (median 0/mL, 
range 0-4/mL, see Figure 2 for representative events in healthy volunteers). CTC clusters were not detected in 
healthy volunteer samples. Figure 3 shows the frequency of traditional CTCs and CTC clusters in patient samples 
compared to healthy volunteer samples.  
ROC curve analysis of traditional CTC counts, CTC clusters (as well as other non-traditional CTCs as 
described below) to discriminate healthy volunteers from mCRPC patients—although not the intended use of the 
assay— was performed for each traditional and non-traditional CTC type. The area under the curve (AUC) for 
prediction of CRPC status for traditional CTCs (CTCs/mL), CTC clusters, CK- CTCs, apoptotic CTCs and all 
CTCs was 0.93 (Youden index 0.71 at >0 CTCs/mL), 0.59 (Youden index 0.17 at >0 CTCs/mL), 0.91 (Youden 
index 0.78 at >0 CTCs/mL), 0.91 (Youden index 0.74 at >4 CTCs/mL) and 0.96 (Youden index 0.76 at >4 
CTCs/mL), as shown in Table 2..  
 
Phenotypic and Molecular Characterization of Traditional CTCs   
AR over-expression, loss of PTEN, and ERG rearrangements (most commonly resulting in TMPRSS2:ERG 
gene fusions) are common molecular events in mCRPC and can be used to confirm captured cells are CTCs, 
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especially ERG rearrangements that are PCa specific [12-15]. AR expression was evaluated in all mCRPC patients 
and select healthy volunteers. To generate a relative AR expression value for each CTC, Epic’s software 
normalized AR expression in CTCs to approximately 1 million surrounding CD45+ WBCs present on the same 
slide, resulting in CTCs with AR expression values ≥3.0 being considered positive. Across the 41 mCRPC patients, 
28 (68%) had at least one AR-positive traditional CTC/mL (range 0-96) (Figure 4A). The proportion of AR+ to 
AR- traditional CTCs was variable (Figure 4B). Of six healthy volunteer samples tested, none had >1 AR+ 
CTC/mL.  
To further establish the prostatic origin of CTCs in our cohort, we also assessed PTEN and ERG status by 
FISH, using surrounding WBCs as internal controls. To determine assay specificity, we assessed PTEN and ERG 
status of WBCs from patient slides tested by FISH. Of 120 patient WBCs evaluated for PTEN FISH, 3 (2.5%) and 0 
(0.0%) cells were detected with PTEN heterozygous (HE) and homozygous (HO) loss, respectively, resulting in 
97.5-100% specificity of PTEN FISH on the Epic platform. Of 220 patient WBCs evaluated with ERG FISH, 10 
(4.5%) and 0 (0.0%) cells had a split signal or loss of the 5’ probe confirming 95.5-100% specificity.  
After IF staining for CTC and AR detection on the Epic platform, CTCs from select mCRPC patients were 
then re-located and evaluated for PTEN and/or ERG FISH status. PTEN deletions (HE and/or HO) were detected in 
traditional CTCs from 4 of 5 patients evaluated (Table 3). Likewise, ERG rearrangements (translocation and/or 
deletion) were identified in traditional CTCs from 5 of 6 patients evaluated (Table 3). Representative images of 
traditional CTCs with AR expression and/or PTEN deletion or ERG rearrangement are shown in Figure 1. Among 
slides from healthy volunteers, none had sufficient detectable CTCs to perform PTEN or ERG assessment. 
PTEN FISH was performed on 5 representative patients with CK- CTCs and we were able to evaluate 18 
CK- CTCs from 3 patients. Of 3 patients with evaluable CK- CTCs, PTEN deletions were identified in 1 patient, 
with 5/9 (56%) CK- CTCs showing PTEN deletion. PTEN deletions were also detected in 4/11 (36%) traditional 
CTCs from this patient. ERG FISH was performed on 6 representative patients with CK- CTCs and we were able to 
evaluate 26 CK- CTCs from 5 patients. Of 5 patients with evaluable CK- CTCs, ERG rearrangements were 
identified in 3 patients, with 3/26 (12%) CK- CTCs showing ERG rearrangement. ERG rearrangements were also 
detected in 18/108 (17%) traditional CTCs from these 3 patients.  
Small CTCs were evaluated in select patient samples by FISH for ERG and PTEN aberrations. ERG FISH 
was performed on 6 patients with small CTCs and we were able to evaluate 27 small CTCs from 3 patients. Of 
these, ERG rearrangements were detected in 1 patient in 6/23 (26%) small CTCs. ERG rearrangements were also 
detected in 18/73 (25%) traditional CTCs (non-small) from this patient. The size of small CTCs precluded 
interpretation of PTEN deletions in all but 3 small CTCs in 2 patients, which were wild type. Examples of small 
CTCs harbouring AR positivity by IF or ERG alterations by FISH are shown in Figure 1.Importantly, these results 
demonstrate the utility of this assay to characterize CTC populations with cancer-specific markers, verifying the 
prostatic origin of traditional CTCs in this cohort. 
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Detection of Non-traditional CTCs in mCRPC patients 
As described in detail below, we identified two categories of cells with non-traditional phenotypes (in 
addition to CTC clusters) that were potential CTCs: cells with weak or no CK expression (CK- CTCs), and cells 
with degenerative changes and nuclear disintegration consistent with apoptosis (apoptotic CTCs). All patients 
harboured circulating cells with these non-traditional phenotypes (median 6/mL, range 1-101). Four of 20 (20%) 
healthy volunteers had circulating cells that met these expanded CTC criteria (median 0/mL, range 0-5) and 3/20 
(15%) had cells with AR positivity (median 0/mL per patient, range 0-4). Figure 3 shows the frequency of non-
traditional CTCs in patient samples compared to healthy volunteer samples. For all non-traditional CTCs, AR 
expression was evaluated by IF and showed a wide variability similar to traditional CTCs (Figure 4A). 
Representative images of non-traditional CTCs, including those with PCa specific molecular alterations, are shown 
in Figure 1.  
 
Cytokeratin-negative CTCs 
CK intensity in CD45- circulating cells with abnormal morphology varied widely across patients with 
mCRPC (Figure 4C). As with AR expression measurements, relative CK expression values for every CTC were 
generated by Epic’s software, normalizing CK expression in CTCs to approximately 1 million surrounding CD45+ 
WBCs present on the same slide. CTCs with CK expression values ≥2.8 were considered positive (signal ≥ 2.8 fold 
higher than background WBCs). Hence, we defined non-traditional CK- CTCs as CD45- circulating cells with 
morphological distinction and/or AR positivity, but CK intensity less than 2.8. Such CK- CTCs were identified in 
34/41 (83%) mCRPC patients (median 2 CK- CTC/mL, range 0-20). Amongst patients with CK- CTCs, 26 (76%) 
had at least 1 AR+ CK- CTC/mL (range 0-20). The proportion of CK+/CK- CTCs varied across the cohort, with two 
patients demonstrating a CTC population that was predominantly CK- (Figure 4D). Of healthy volunteers 
evaluated, none had >1 CD45-/CK- cell/mL. Both ERG rearrangements and PTEN deletions were detected in CK- 
CTCs from mCRPC patients who harboured these same alterations in traditional CTCs (Table 3).  
 
Apoptotic and Small CTCs  
CD45-/CK+ cells with nuclear fragmentation or condensation characteristic of apoptosis were also observed 
across the mCRPC cohort. These cells, which we classified as non-traditional apoptotic CTCs, were detected in 
40/41 (98%) of mCRPC patients (median 4/mL, range 0-92) as shown in Figure 3. Of the 40 patients with 
apoptotic CTCs, 31 (78%) had at least 1 AR+ apoptotic CTC/mL (range 0-60). Similar to the other categories of 
non-traditional CTCs, the frequency of apoptotic CTCs varied among mCRPC patients, with 11/41 (27%) patients 
exhibiting CTC populations composed primarily of apoptotic CTCs (Figure 4E). Due to nuclear fragmentation or 
disintegration, apoptotic CTCs were not amenable to FISH analysis.  
 We then utilized Epic software to objectively measure the total cell area of each CTC to elucidate the 
subpopulations of CTCs in patient samples that were similar in size to (or smaller than) WBCs, that could 
potentially be missed by size or density enrichment strategies for CTC isolation. Approximately 300 patient WBCs 
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were used to generate the median and interquartile ranges for WBC area (75 µm2 and 64-90 µm2, respectively). We 
therefore used a cell area ≤ 90 µm2 to define a small CTC (Figure 5A). By this approach, cell area of traditional and 
non-traditional CTC subtypes was evaluated for 40/41 patient samples (1 sample was not evaluable by this method 
and omitted from analysis). Apoptotic CTCs were omitted from analysis because of poor segmentation due to 
fragmented cell morphology. We observed a wide range of CTC sizes within individual patients and across the 
mCRPC patient cohort using this objective assessment, with small CTCs detectable in 39/40 (97.5%) mCRPC 
patients. CTCs detected in mCRPC patients had a median cell area of 99.0 µm2 (range 28.9-1631.0). The proportion 
of small CTCs (CTCs with cell area ≤ 90 µm2) is shown for each patient in Figure 5B, with 17/40 (42.5%) patients 
exhibiting CTC populations composed predominantly of small CTCs. Small CTCs were evaluated in select patient 
samples by FISH for ERG and PTEN aberrations (Table 3). Examples of small CTCs harbouring AR positivity by 
IF or ERG alterations by FISH are shown in Figure 1. 
 
Clinical significance of CTC types  
 Although the main focus of our work was to define the morphologic and phenotypic range of CTCs in 
patients with mCRPC using an unbiased approach complemented by molecular characterization, we also assessed 
associations between traditional and non-traditional CTC types and clinicopathological parameters (serum prostate-
specific antigen (PSA), lactate dehydrogenase (LDH), albumin and hemoglobin levels, as well as prior treatment 
regimens and presence of visceral metastasis). Importantly, as shown in Figure 6A, this analysis demonstrated that 
counts of all CTC types detected by the Epic platform (traditional, CTC clusters, and each non-traditional CTC 
type, as well as the sum of all CTCs) are significantly correlated with each other, ranging from Spearman rank 
correlation (rs) = 0.35 for apoptotic CTC and CTC cluster counts (p=0.03), to rs=0.72 for traditional CTC and 
apoptotic CTC counts (p<0.0001). Of interest, there was no significant correlation between any CTC type count and 
serum PSA levels. However, counts of CTC types other than CTC clusters were significantly associated with high 
LDH and low albumin, two important prognostic parameters. Likewise, both all CTC (sum of traditional CTCs, 
CTC clusters, apoptotic CTCs and CK- CTCs) and apoptotic CTC counts were significantly associated with the 
presence of visceral metastasis Figure 6B. We did not identify a statistically significant difference between any 
CTC type count and prior treatment regimen.  
 Next, we assessed correlations between CTC counts by the CellSearch Circulating Tumor Cell System and 
the Epic platform in the mCRPC cohort. Importantly, as shown in Table 4, we observed strong correlation between 
traditional CTC counts by CellSearch and traditional CTCs by the Epic platform in the mCRPC patients (Pearson’s 
correlation r
 
= 0.78, p<0.0001). Likewise, we also observed significant correlations between CellSearch CTC 
counts and apoptotic (Pearson’s correlation r = 0.91, p<0.0001) or CK- CTC counts (r = 0.39, p=0.02) by the Epic 
platform (Table 4). No significant correlation was observed between CellSearch CTC counts  and CTC cluster 
counts (r = -0.07, p=0.68) by the Epic platform, although CTC clusters were infrequently observed in our cohort. 
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Importantly, we identified a strong, significant correlation between CellSearch CTC counts and total CTC counts 
by the Epic Platform (r = 0.89, p<0.0001, Table 4).     
 Lastly, to provide preliminary insight into associations with clinical outcome, we determined CTC counts 
by the Epic Platform in mCRPC patients who were alive or dead after 18 months (40 of 41 patients with sufficient 
follow-up). As shown in Figure 6C, total, traditional and non-traditional (clusters, apoptotic and CK-) CTC counts 
were significantly higher in patients dead versus alive at 18 months (Mann-Whitney test, p=0.02, p=0.03 and 
p=0.04, respectively). By Kaplan-Meier analysis on all 41 patients, the number of non-traditional CTCs was 
significantly associated with overall survival (, > vs. ≤ median CTC count, p=0.03, Fig 4D).   Results for individual 
non-traditional CTC types are shown in Figure 7. Of interest, there were 14 patients with <5 CTCs detected by the 
CellSearch assay, of which 4 were deceased at 18 months; each of these deceased patients demonstrated non-
traditional CTC cells as detected by the Epic platform.  
 
DISCUSSION 
To characterize the phenotypic diversity of CTCs in mCRPC, we used the Epic platform to characterize all 
nucleated cells from whole blood samples [20]. Using DAPI, CD45, CK and AR IF, we identified and 
morphologically characterized cells with cancer-associated features, irrespective of whether they met the traditional 
CTC definition. We then used FISH and slide scanning with single-cell resolution to confirm that sub-populations 
of non-traditional CTCs were PCa in origin. We detected non-traditional CTC in all patients, including CTC 
clusters, small, apoptotic and/or CK- CTCs. We also observed intra-patient heterogeneity of AR and CK expression 
and PTEN and ERG status consistent with a heterogeneous model of advanced disease, as has been observed in 
recent studies of CRPC assessing AR expression in CellSearch-isolated CTCs, metastatic tissues assessed by whole 
genome sequencing, and circulating cell free DNA assessed using targeted next generation sequencing [21-23].  
Although non-traditional CTC counts correlated with traditional CTC counts, substantial variation in the 
proportions of traditional to non-traditional CTCs were observed. Importantly, some CTCs we identified could be 
missed by CTC detection platforms using antigen capture (i.e. EpCAM or CK) or size selection (such as filtration). 
In keeping with this idea, Chen et al., recently reported that EpCAM captured CTCs (enriched using NanoVelcro 
Chips) in patients with mCRPC showed variable nuclear size, and patients with visceral metastases specifically 
showed elevated very small nuclear sized CTCs [8]. Our results suggest that in addition to nuclear size variability, 
CTCs in mCRPC patients show considerable heterogeneity in nuclear organization, and CK and AR expression. 
CK+/CD45- cells were identified in a small minority of healthy volunteer samples at low frequencies, with 
the majority demonstrating low CK and AR expression. Given no universally established reference range for the 
definition of CTC, nor a recognized pan-CTC marker, it is difficult to discern the relevance of these cells in healthy 
volunteers. CTC-like cells can be detected in the blood of patients with benign conditions as well as in those with 
early stage disease [24-26], and have been reported in labelled healthy volunteers [27]. The ideal healthy volunteer 
or non-cancer control population would be matched in age and demographics, with confirmed absence of 
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malignancy. While these caveats are impediments for utilizing any CTC platform for the primary diagnosis of 
prostate cancer, the increased sensitivity and specificity of the Epic platform for CTC detection could be suited for 
acquiring prognostic and predictive information in mCRPC patients. 
       Detection of significant non-traditional CTC populations in mCRPC patients is consistent with substantial 
evidence supporting their existence and clinical relevance. For example, CTCs postulated to have undergone 
epithelial to mesenchymal transition (EMT), and displaying reduced/no EpCAM or CK expression, have been 
identified by multiple platforms using both cell lines and patient samples [27-33]. These cells may be enriched for 
multipotent cancer stem cells, with increased self-renewal and metastasis forming capacity [34, 35]. Although prior 
studies demonstrate substantial heterogeneity of PTEN deletion status in CTCs and CRPC tissue foci in a given 
patient [12, 36], ERG rearrangements have generally been identified as a clonal alteration (when present) in both 
CTCs and mCRPC tissues [12, 21, 37-39]. Possible explanations for these apparently discrepant results include 
increased sensitivity for traditional and non-traditional CTCs (identified here) that may represent multiple clonal 
populations when compared to our previous CellSearch based study showing homogeneous ERG status in 
traditional CTCs [12]. Also, our recent study on circulating cell-free DNA in patients with mCRPC supported the 
existence of both ERG rearranged and wildtype clones in the same patient during disease progression [23]. This 
contrasts with the observation that multiple CRPC foci at autopsy in an individual patient nearly always show 
homogeneous ERG status. Further studies are required to interrogate this difference, which we hypothesize could be 
informed by more comprehensive genetic analysis of individual traditional and non-traditional CTC populations. 
Our cohort represents a single institution mCRPC cohort and the relatively small size in this non-uniformly 
treated initial study limits the ability to draw robust conclusions on associations between non-traditional CTCs and 
clinical outcome. Likewise, additional studies are needed to characterize the metastatic potential of distinct CTC 
classes. Importantly, evaluation of these distinct CTC populations described here in larger, well-defined cohorts to 
inform on their prognostic and predictive utility in mCRPC is now warranted. Here, using pathologic and molecular 
biological approaches, we have described expanded categories of CTC phenotypes in patients with mCRPC and 
demonstrate that considerable heterogeneity exists within these categories.   These expanded CTC subtypes may 
provide novel prognostic and predictive information for patients with mCRPC, as well as other advanced cancers.  
Intriguing preliminary clinical associations between mCRPC outcomes and various CTC subpopulations will need 
to be assessed in additional ongoing and planned studies to expand on our study. 
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Table 1. Demographic and clinical characteristics of patients and healthy volunteers at the time of study 
inclusion  
CRPC patients n=41 
Age (yr)   
Median 70 
Range 40-82 
Serum PSA (ng/mL)   
Median 90 
Range 2-2532 
LDH (U/L)   
Median 170 
Range 112-678 
Albumin (g/L)   
Median 35 
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Range 24-42 
Haemoglobin (g/dL)  
Median 12.2 
Range 8.3-15.5 
Sites of metastases   
Bone 39 (95%) 
Nodal 28 (68%) 
Visceral 13 (32%) 
ECOG performance score   
0 6 (15%) 
1 33 (80%) 
2 2 (5%) 
Previous CRPC therapies (n)   
Median 3 
Range 1-5 
Previous therapies   
Bicalutamide 41 (100%) 
Docetaxel 26 (63%) 
Cabazitaxel 4 (10%) 
Abiraterone (AA) 14 (34%) 
Enzalutamide (E) 3 (7%) 
Investigational agents 13 (32%) 
Healthy Volunteers n=20 
Age (yr)   
Median 33.5 
Range 21-53 
Sex   
Male 10 
Female 10 
CRPC = castration resistant prostate cancer 
 
 
Table 2. Receiver operator characteristic curve (ROC) analysis of circulating tumor cell (CTC) counts for 
discriminating healthy volunteers and patients with castration resistant prostate cancer (CRPC) 
 
  
ROC Youden index 100% Sensitivity 100% Specificity 
CTC type AUC 95% CI Value 
CTC/mL 
cutoff 
CTC/mL 
cutoff 
Specificity 
CTC/mL 
cutoff 
Sensitivity 
All CTCs 0.96 (0.88-0.99) 0.76 >4 >0 71% >9 56% 
Traditional 
CTCs 
0.93 (0.84-0.98) 0.71 >0 >0 71% >4 54% 
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Apoptotic 
CTCs 
0.91 (0.81-0.97) 0.74 >0 N/A N/A >5 39% 
CK- CTCs 0.91 (0.81-0.97) 0.78 >0 N/A N/A >1 63% 
CTC 
Clusters 
0.59 (0.45-0.71) 0.17 >0 N/A N/A >0 17% 
ROC curves were generated from CTC/mL counts for indicated CTC types (All CTCs is the sum of the other 4 types) for 
predicting CRPC status in 21 healthy volunteer samples (from 20 patients) and 41 CRPC samples. Cell size was not 
included in this analysis (all categories may include small nuclear sized CTCs). Area under the curve (AUC) and 95% 
confidence intervals (CI) are given, along with Youden index values and CTC/mL cutoffs. CTC/mL cutoffs for 100% 
sensitivity and specificity are given, along with corresponding specificity and sensitivity.  
 
Table 3. FISH characterization of prostate cancer specific molecular alterations (PTEN deletions top; ERG 
rearrangements bottom) in phenotypically diverse CTCs in patients with mCRPC 
Patient  Cell Type PTEN 
evaluable cells 
AR+ 
cells  
PTEN 
heterozygous cells  
PTEN 
homozygous cells 
1PTEN deletion 
cells  
     (n) (%)  (n)  (n) (%) 
  Traditional  7 14% 2 0 29% 
V4004* CK-  0 N/A N/A N/A N/A 
  Small  0 N/A N/A N/A N/A 
  Traditional  32 0% 1 0 3% 
V5035 CK-  4 25% 0 0 0% 
  Small  1 0% 0 0 0% 
  Traditional  11 36% 0 4 37% 
V5042* CK-  9 44% 1 4 56% 
  Small  2 0% 0 0 0% 
  Traditional  12 0% 1 1 17% 
V5131 CK-  5 0% 0 0 0% 
  Small  0 N/A N/A N/A N/A 
  Traditional  13 0% 0 0 0% 
V5055 CK-  0 N/A N/A N/A N/A 
  Small  0 N/A N/A N/A N/A 
Patient  Cell Type ERG evaluable 
cells 
AR+ 
cells  
ERG 5' deletion 
cells  
ERG 5'/3' split 
cells  
2ERG rearranged 
cells  
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     (n) (%)  (n)  (n) (%) 
  Traditional 11 0%** 0 0 0% 
V4048 CK- 0 N/A N/A N/A N/A 
  Small  0 N/A N/A N/A N/A 
  Traditional  73 73% 6 12 25% 
V5025* CK-  10 90% 0 0 0% 
  Small  23 48% 2 4 26% 
  Traditional  35 63% 4 7 31% 
V5083 CK-  2 100% 0 1 50% 
  Small  3 0% 0 0 0% 
  Traditional  64 94% 0 4 6% 
V5085* CK- 6 83% 0 1 17% 
  Small  0 N/A N/A N/A N/A 
  Traditional  9 56% 0 3 33% 
V5106 CK-  1 100% 0 1 100% 
  Small  0 N/A N/A N/A N/A 
  Traditional  21 0% 0 3 14% 
5131* CK-  7 0% 0 0 N/A 
  Small  1 100% 0 0 N/A 
FISH analysis for prostate cancer specific alterations was performed on selected patients. The percentage of CTCs 
(stratified by CTC type) with androgen receptor (AR) positivity by immunofluorescence (IF) is given for patients 
assessed for PTEN loss (top panel) or ERG rearrangement (bottom) by FISH. False positive PTEN HE and HO rate in 
white blood cells (WBCs) 2.5% (3/120 WBCs) and 0% (0/120 WBCs), respectively. False positive ERG 5' deletion and 
5'/3' split rate 0% (0/220 WBCs) and 4.5% (10/220 WBCs), respectively. 1Including both HE and HO cells. 2Both 5' 
deletion and 5'/3' split cells. *Additional slides beyond the standard 2 slides were used for FISH evaluation. **3 cells 
were unevaluable for AR expression.  
 
 
 
 
 
 
Table 4. CTC counts by Epic vs. CellSearch platforms in mCRPC patients 
  CellSearch Epic CTC counts 
Patient CTCs/7 mL Traditional 
CTCs/mL 
CTC 
Clusters /mL 
CK-            
CTCs/mL 
Apoptotic 
CTCs/mL 
All       
CTCs/mL 
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V4002 NA 2 0 1 1 4 
V4004 2 9 3 1 6 19 
V4030 NA 7 0 1 7 15 
V4045 NA 1 0 10 2 13 
V4048 12 9 0 2 9 20 
V4082 5 1 0 2 3 6 
V5025 157 54 1 11 5 71 
V5031 NA 1 0 1 3 5 
V5035 1 57 6 14 10 87 
V5037 0 4 0 3 2 9 
V5039 27 6 0 2 4 12 
V5042 285 8 0 1 14 23 
V5054 11 1 0 2 4 7 
V5055 52 26 2 3 6 37 
V5058 1 1 0 3 1 5 
V5061 6 3 0 2 4 9 
V5066 NA 2 0 1 3 6 
V5069 70 27 0 5 16 48 
V5070 1 3 0 0 6 9 
V5071 6 2 0 0 3 5 
V5074 18 5 0 0 2 7 
V5076 1 2 0 0 1 3 
V5080 3 2 0 0 3 5 
V5083 646 59 0 9 78 146 
V5085 563 121 0 17 42 180 
V5086 26 3 0 1 3 7 
V5088 0 5 0 8 7 20 
V5102 5 4 0 5 2 11 
V5106 448 55 0 4 45 104 
V5107 568 49 1 9 92 151 
V5108 1 1 0 0 3 4 
V5110 0 4 0 2 3 9 
V5111 0 13 1 7 9 30 
V5122 0 5 0 20 15 40 
V5126 5 2 0 2 2 6 
V5127 95 15 0 4 4 23 
V5131 0 17 2 9 5 33 
V5133 12 8 0 3 1 13 
V5135 2 10 0 6 7 23 
V5145 34 1 0 1 0 2 
V5148 21 8 0 0 2 10 
       
 
 
Correlation with 
CellSearch: 
0.78 -0.07 0.39 0.91 0.89 
 
p value: <0.0001 0.68 0.02 <0.0001 <0.0001 
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Circulating tumour cell (CTC) counts for 41 patients with metastatic castration resistant prostate cancer 
(mCRPC) as determined by the CellSearch and Epic platforms are given. For Epic determined CTC counts, 
counts for traditional CTCs, non-traditional CTCs (CTC clusters, apoptotic CTCs and CK- CTCs) and all CTCs 
(sum of traditional and non-traditional CTCs) are given. NA = not available. Pearson correlation and p values of 
CellSearch counts with each Epic CTC category across the cohort are given below the table.   
 
 
FIGURE LEGENDS 
 
Figure 1. Patients with metastatic castration resistant prostate cancer (mCRPC) harbour traditional and 
non-traditional CTCs with prostate cancer specific molecular alterations. A. Representative 
immunofluorescence (IF) image (100X magnification) examples of traditional and non-traditional CTCs in mCRPC 
patient samples (positive androgen receptor (AR) staining by IF is shown for each CTC). Traditional (DAPI+/CD45-
/cytokeratin [CK]+/abnormal morphology), cluster (two or more adjacent traditional CTCs), small (DAPI+/CD45-
/CK+/small cellular area), CK- (DAPI+/CD45-/CK-/AR+/abnormal morphology), and apoptotic (DAPI+/CD45-
/CK+/nuclear disintegration/abnormal morphology) CTCs from mCRPC patient samples are shown. B. Example 
photomicrographs (400X magnification) of ERG and PTEN molecular alterations detected by fluorescence in situ 
hybridization (FISH) in traditional and non-traditional CTCs from mCRPC patient samples are shown (inset images 
(100X magnification) show CTC prior to FISH). PTEN deletions are indicated by loss of the PTEN locus green 
signal) in the presence of chromosome 10 centromeric signal (CEP 10, red). ERG rearrangements can be identified 
by 5’ deletion (resulting in loss of 5’ green signal; far left panel) or by split 5’/3’ signals (centre and second from 
right panel).  
 
Figure 2.  CTC-like cells detected in healthy volunteers. Representative immunofluorescence (IF) examples 
(100x magnification) of traditional and non-traditional CTC-like cells in healthy volunteer samples. Traditional 
(DAPI+/CD45-/cytokeratin [CK]+/abnormal morphology), CK- (DAPI+/CD45-/CK-/AR+/abnormal morphology), 
and apoptotic (DAPI+/CD45-/CK+/nuclear disintegration/abnormal morphology) CTC-like cells from healthy 
volunteers are shown. Blue = DAPI, green = CD45, Red = CK, White = AR.    
 
Figure 3. CTC incidence in mCRPC patient samples compared to healthy volunteers (HV) . A. The number of 
traditional CTCs, CTC clusters, CK- CTCs, apoptotic CTCs and all CTC candidates (traditional, clusters, CK-, and 
apoptotic CTCs)/mL identified in HV and mCRPC patient samples are plotted. Black lines indicate the median 
CTCs/mL. B. Range, median, and mean CTCs/mL in mCRPC patient samples for all categories are given.  
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Figure 4. AR and CK expression by immunofluorescence varies across traditional and non-traditional CTCs 
in mCRPC patient samples. AR (A&B) and CK (C&D) intensity distribution across traditional and non-
traditional CTCs per patient. The dashed lines at 3 (A) and 2.8 units (C) indicate the cut-off for AR and CK 
positivity, respectively. Charts B and D show the percentage of all CTCs/mL (traditional and non-traditional) with 
or without B) AR or D) CK expression per patient. E. The percentage of apoptotic and non-apoptotic CTCs/mL per 
patient. 
 
Figure 5. CTC size varies greatly across patients with mCRPC. A. Cellular area (µm2) per CTC as calculated by 
Epic software for each patient is plotted. White blood cell (WBC) size frequency distribution curve was generated 
by measuring the cellular area of approximately 300 normal WBCs (right side). The blue dashed line represents the 
median WBC area (75 µm2). Red and green dashed lines indicate WBC size cut-offs equal to the 25th (64 µm2) and 
75th (90 µm2) percentile, respectively. Traditional CTCs (blue), CTC clusters (green) and CK- CTCs (purple) are 
indicated according to the legend. Apoptotic CTCs were omitted from analysis due to poor segmentation of 
fragmented nuclei in these cells. B. The percentage of all CTCs for each patient with area greater than (non-Small 
CTC; green) or less than the WBC 75th percentile (Small CTC; red) is plotted. *Sample 5037 was not evaluable and 
is not included in panel A.  
 
Figure 6. Associations of CTC/mL counts and clinicopathological parameters. A. Spearman rank correlation 
(rs) matrix of CTC/mL counts (All=summed traditional, clusters, CK- and apoptotic) and clinicopathological 
parameters for the 41 patients with mCRPC in our cohort. Correlations are given and indicated according to the 
colour scale in the legend). Statistical significance of each comparison is indicated by the cell border thickness 
according to the legend. B. Significant (p<0.05, Mann-Whitney test) associations between CTC counts (and 
clinicopathological parameters) with the presence/absence of visceral metastases are shown. C. All, traditional and 
non-traditional CTC counts stratified by patient status (dead vs. alive) at 18 months are plotted (40 of 41 patients 
evaluable at that time point). p values from Mann-Whitney tests are shown. D. Kaplan-Meier analysis for all, 
traditional, and non-traditional CTC counts for overall survival time for all 41 patients. For each CTC type, patients 
were stratified by having > or ≤ median CTC count/mL. Log-rank test p values are shown. Plots for each non-
traditional CTC type for C&D are shown in Figure S2.  
 
Figure 7. Associations of non-traditional CTC/mL counts in patients with mCRPC and overall survival. A. 
Individual non-traditional CTC type counts (CTC clusters, CK- CTCs and apoptotic CTCs) stratified by patient 
status (dead vs. alive) at 18 months are plotted (40 of 41 patients evaluable at that time point). p values from Mann-
Whitney tests are shown. D. Kaplan-Meier analysis for CTC clusters, CK- CTCs and apoptotic CTCs and overall 
survival time for all 41 patients. For each CTC type, patients were stratified by having > or ≤ median CTC 
count/mL. Log-rank test p values are shown.  
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